REG - Cambridge Cognition - Block Listing Return

Cambridge Cognition HoldingsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260401:nRSA9049Ya&default-theme=true

RNS Number : 9049Y  Cambridge Cognition Holdings PLC  01 April 2026

1 April 2026

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Block Listing Return

 

The Company makes the following notification pursuant to AIM Rule 29 and
Schedule Six of the AIM Rules for Companies, regarding its existing block
listings:

 

 Name of applicant:                                                                Cambridge Cognition Holdings plc
 Name of scheme:                                                                   Share Options
 Period of return:                        From:                                    1 October 2025               To:                          31 March 2026
 Number and class of share(s) (amount of stock / debt securities) originally       1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on
 listed and the date of admission:                                                 23 March 2023
 Balance of unallotted securities under scheme(s) from previous return:            466,316 ordinary shares
 Plus:  The amount by which the block scheme(s) has been increased since the       Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        Nil
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        466,316 ordinary shares

 

 Name of contact:              Simon McKeating
 Telephone number of contact:  +44 (0)1223 810700

 

Enquiries:

 Cambridge Cognition Holdings plc                    Tel: +44 1223 810700 

 Rob Baker, Chief Executive Officer                  press@camcog.com (mailto:press@camcog.com)  

 Ronald Openshaw, Chief Financial Officer

 Adam Michael, Head of Corporate Communications
 Panmure Liberum Limited (NOMAD & Joint Broker)      Tel: +44 20 7886 2968

 Will Goode / Mark Rogers / Freddy Crossley          (Corporate Finance)

 Rupert Dearden                                      (Corporate Broking)
 Singer Capital Markets Limited (Joint Broker)       Tel: +44 20 7496 3000

 Amber Higgs / James Serjeant / Daniel Ingram         

 

ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™

Cambridge Cognition is a neuroscience technology company whose digital
cognitive assessments support scientific discovery, accelerate drug
development and improve patient care.

The Company has developed a suite of touchscreen and voice-based cognitive
assessments delivered under the CANTAB and Winterlight brands.  These
assessments are designed to:

●     require minimal specialist administration

●     deliver objective results in real time or shortly after completion

●     reduce administrator bias

●     support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers
in home-use settings and healthcare professionals in clinical or research
environments.

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive
assessment solution, structured as an escalating series of tasks for use in
consumer and healthcare settings:

●     CANTAB One™ - a brief assessment of overall cognitive function

●     CANTAB Insight™ - a three-task battery providing deeper insight
across five cognitive sub-domains

●     CANTAB Plus™ - specialist disease-specific modules for use by
appropriately qualified healthcare professionals, covering eight indications
including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease,
schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEALDFDAPKEFA



            Copyright 2019 Regulatory News Service, all rights reserved